Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Apr 2021 for Pandion Therapeutics, Inc., €107.3M.
Insider track record
Disclosed buys
1
Disclosed sells
0
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Christopher Fuglesang: trading record in brief
All filings by Christopher Fuglesang on record concern Pandion Therapeutics, Inc. In total, 4 filings cover trades dated from 21 July 2020 to 1 April 2021.
On the market, this insider has only ever bought: 1 purchase, €11.3M in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The newest entry dates from 1 April 2021: a transaction of €107.3M, in Pandion Therapeutics, Inc. The latest purchase dates back some time: it was published 2,285 days ago, on 21 July 2020. The median gap between trade and publication is zero days: most filings appear on the same day. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Christopher Fuglesang
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
2,107,513 shares@ US$60.0098.9% of flowCommon StockSEC:0000899243-21-014452:0
23,622 shares@ US$60.001.1% of flowCommon StockSEC:0000899243-21-014452:1
1,408,913 sharesCommon StockSEC:0000899243-20-019882:0
722,222 shares@ US$18.00100.0% of flowCommon StockSEC:0000899243-20-019882:1
Canonical exit: 19 Oct 2020 (T+90)
4 of 3 declarations
